Retatrutide (LY3437943) is an investigational injectable drug from Eli Lilly, a triple hormone agonist activating GIP, GLP-1, and glucagon receptors.
Similar to other GLP-1 medications, retatrutide is an injectable medication that targets hormone receptors in your body that directly impact metabolism and appetite. Retatrutide targets three different receptors:
- GLP-1 (helps regulate appetite and blood sugar)
- GIP (supports insulin response)
- Glucagon (affects energy use and fat metabolism)
By targeting all three, the medication delays how fast your stomach digests food, lowers your appetite, and ultimately reduces how much food you eat. This can lead to numerous improvements in health, including:
- Weight loss
- Improved glycemic control (a.k.a. how well your blood sugar is managed)
- Lower blood pressure
- Better liver and kidney health
But retatrutide does still carry the risk for side effects that most in this category do, most commonly GI issues like nausea, constipation, or vomiting. While higher doses of retatrutide are linked to more weight loss, dosing is titrated up over time, just like with other injectables.
No comments:
Post a Comment